Search results for "bacteri"

showing 10 items of 5466 documents

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

2008

Patients suffering from cystic fibrosis (CF) often need to inhale multiple doses of different nebulizable drugs per day. Patients attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. The objective of this experimental study was to determine whether mixtures of the nebulizer solution dornase alfa (Pulmozyme) with tobramycin nebulizer solutions (TOBI and GERNEBCIN 80 mg) are physico-chemically compatible. Drug combinations were prepared by mixing the content of one respule Pulmozyme with either one respule TOBI or one ampoule GERNEBCIN 80 mg. Test solutions were stored at room temperature and exposed to light. Dornase…

Pulmonary and Respiratory MedicineChemical PhenomenaCystic FibrosisExcipientAmpouleDrug Incompatibilitychemistry.chemical_compoundAdministration InhalationTobramycinDeoxyribonuclease IHumansMedicinePotencyChromatographyInhalationbusiness.industryNebulizers and VaporizersDornase alfaSodium metabisulfiteAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionsNebulizerchemistryAnesthesiaPediatrics Perinatology and Child HealthTobramycinbusinessmedicine.drugPediatric Pulmonology
researchProduct

Permanent Loss of Human Leukocyte Antigen E–restricted CD8+ T Stem Memory Cells in Human Tuberculosis

2022

Pulmonary and Respiratory MedicineHLA AntigensHLA-EClinical BiochemistryTuberculosisMycobacterium tuberculosisStem cellsCell BiologyCD8-Positive T-LymphocytesMolecular BiologyAmerican Journal of Respiratory Cell and Molecular Biology
researchProduct

Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.

2019

Background Community-acquired pneumonia (CAP) increases the risk of cardiovascular complications during and following the episode. The goal of this study was to determine the usefulness of cardiovascular and inflammatory biomarkers for assessing the risk of early (within 30 days) or long-term (1-year follow-up) cardiovascular events. Methods A total of 730 hospitalized patients with CAP were prospectively followed up during 1 year. Cardiovascular (proadrenomedullin [proADM], pro-B-type natriuretic peptide (proBNP), proendothelin-1, and troponin T) and inflammatory (interleukin 6 [IL-6], C-reactive protein, and procalcitonin) biomarkers were measured on day 1, at day 4/5, and at day 30. Resu…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyTime Factorsmedicine.drug_classCritical Care and Intensive Care MedicineRisk AssessmentProcalcitonin03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicineNatriuretic peptidePneumonia BacterialMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedAged 80 and overbiologyTroponin Tbusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseTroponinCommunity-Acquired InfectionsPneumonia030228 respiratory systemCardiovascular Diseasesbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersChest
researchProduct

Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.

2012

The objective of this in-vitro study was to determine whether admixtures of the inhalation solutions Pulmozyme(®) (Dornase alfa) and either Bramitob(®) or Tobi(®) (both containing Tobramycin) are physicochemically compatible and to analyze the aerodynamic parameters of these admixtures. After mixing, test solutions were stored at room temperature and under ambient light conditions over a period of 24 h. Tobramycin concentrations were determined by using a fluorescence immunoassay. Stability of dornase alfa was determined by size-exclusion high performance liquid chromatography, ultraviolet spectroscopy, sodium dodecyl sulfate polyacrylamide gel electrophoresis and tentacle strong cation-exc…

Pulmonary and Respiratory MedicineTime FactorsDrug StorageHigh-performance liquid chromatographyDrug Incompatibilitychemistry.chemical_compoundDrug StabilityAdministration InhalationmedicineTobramycinGeometric standard deviationDeoxyribonuclease IPharmacology (medical)Sodium dodecyl sulfateParticle SizeAerosolsChromatographyInhalationNebulizers and VaporizersBiochemistry (medical)Osmolar ConcentrationDornase alfaHydrogen-Ion ConcentrationRecombinant ProteinsAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionschemistryCompatibility (mechanics)TobramycinFeasibility StudiesParticle fractionmedicine.drugPulmonary pharmacologytherapeutics
researchProduct

Urticaria and bacterial infections

2014

The association between urticaria and infectious diseases has been discussed for >100 years. However, a causal relationship with underlying or precipitating infection is difficult to establish. The purpose of this work was to perform a systematic analysis of the published cases of urticaria associated with bacterial infections. We give an umbrella breakdown of up-to-date systematic reviews and other important publications on the complex association of urticaria and bacterial infections. We did a Medline search, for English language articles published until January 2014, using the key words "urticaria" and "bacteria/bacterial disease"; a second analysis was performed in groups of bacteria an…

Pulmonary and Respiratory MedicineUrticariaPATHOGENESISCHILDRENBrucellaLyme diseaseANGIOEDEMAimmune system diseasesHELICOBACTER-PYLORIMYCOPLASMA-PNEUMONIAE INFECTION; HELICOBACTER-PYLORI; LYME-DISEASE; ANGIOEDEMA; CHILDREN; BRUCELLOSIS; VASCULITIS; MANIFESTATIONS; PATHOGENESIS; EOSINOPHILIAparasitic diseasesHumansImmunology and AllergyMedicineVASCULITISskin and connective tissue diseasesBRUCELLOSISBacterial diseaseChlamydiaEOSINOPHILIAAngioedemabiologybusiness.industryLYME-DISEASEBacterial InfectionsGeneral MedicineHelicobacter pylorimedicine.diseasebiology.organism_classificationMANIFESTATIONSMycoplasma pneumoniaImmunologyMYCOPLASMA-PNEUMONIAE INFECTIONmedicine.symptombusinessPneumonia (non-human)
researchProduct

Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma.

2005

Exacerbations are an important cause of the morbidity and mortality associated with asthma and chronic obstructive pulmonary disease. Newer therapies include long-acting beta(2)-agonists, which are more effective than short-acting bronchodilators. Inhaled corticosteroids and, in asthma, leukotriene receptor antagonists may have roles in the early phase of exacerbation as an alternative to or added to oral prednisolone. In the future, combinations of long-acting beta(2)-agonists and anticholinergic bronchodilators may offer additive clinical benefits. However, although the treatment and prevention of exacerbations of chronic obstructive pulmonary disease and asthma have been improved by usin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationPulmonary diseaseInhaled corticosteroidsPulmonary Disease Chronic ObstructivePharmacotherapyAdrenal Cortex HormonesmedicineHumansPharmacologic therapyAnti-Asthmatic AgentsIntensive care medicineAsthmabusiness.industryAdrenergic beta-Agonistsmedicine.diseaseAsthmaAnti-Bacterial AgentsBronchodilator AgentsDrug CombinationsEtiologyDisease ProgressionLeukotriene AntagonistsDrug Therapy CombinationEarly phasebusinessForecastingProceedings of the American Thoracic Society
researchProduct

Host-directed therapies and holistic care for tuberculosis

2020

Pulmonary and Respiratory Medicinemedicine.medical_specialtyTuberculosisbusiness.industryAntitubercular AgentsMEDLINEHolistic HealthMycobacterium tuberculosisHolistic healthmedicine.diseaseHost-Pathogen InteractionsTuberculosis Multidrug-ResistantmedicineHumansIntensive care medicinebusinessHost (network)The Lancet Respiratory Medicine
researchProduct

Tuberculosis Following Lung Transplantation. A 27-Year Spanish Multicenter Experience. Incidence, Presentation, Prevention and Treatment with Rifampi…

2020

Abstract Background Tuberculosis (TB) represents a diagnostic and therapeutic challenge for solid organ transplant recipients, particularly after lung transplant (LT). Our aim was to determine the impact of TB in LT patients in Spain, considering prevalence, clinical presentation, prevention and therapeutic management. In addition, differences in outcome between rifampicin (RIF) versus non-RIF containing regimens were analyzed. Methods Multicenter, observational retrospective study, including all cases of TB diagnosed in recipients after LT, in five pulmonary transplant units in Spain, between January 1990 and December 2017. Results Among 2962 LT recipients, 45 cases of TB were diagnosed, r…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyTuberculosismedicine.medical_treatment03 medical and health sciences0302 clinical medicineInternal medicineHumansTuberculosisMedicineLung transplantationRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyGeneral Medicinebacterial infections and mycosesmedicine.diseaseCalcineurinRegimen030228 respiratory systemSpainTrough levelRifampinbusinessRifampicinLung Transplantationmedicine.drugArchivos de Bronconeumología
researchProduct

Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients

2021

International audience; Background: Culture conditions sometimes make it difficult to detect non-tuberculous mycobacteria (NTM), particularly Mycobacterium abscessus, an emerging cystic fibrosis (CF) pathogen. The diagnosis of NTM positive cases not detected by classical culture methods might benefit from the development of a serological assay.Methods: As part of a diagnostic accuracy study, a total of 173 sera CF-patients, including 33 patients with M. abscessus positive cultures, and 31 non-CF healthy controls (HC) were evaluated. Four M. abscessus antigens were used separately, comprising two surface extracts (Interphase (INP) and a TLR2 positive extract (TLR2eF)) and two recombinant pro…

Pulmonary and Respiratory Medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]Mycobacterium Infections NontuberculousMycobacterium abscessusCystic fibrosisGastroenterologyCystic fibrosisSerology03 medical and health sciences0302 clinical medicineAntigenInternal medicineNon-tuberculous mycobacteriamedicineHumans030212 general & internal medicinePathogenComputingMilieux_MISCELLANEOUSSerodiagnosisMycobacterium abscessusbiologybusiness.industryAntibody titerNontuberculous Mycobacteriamedicine.diseasebiology.organism_classificationbacterial infections and mycoses3. Good healthMycobacterium abscessus InfectionsSerology030228 respiratory systemSerological biomarkersPediatrics Perinatology and Child HealthELISAbusinessBiomarkers
researchProduct

Rho protein inactivation induced apoptosis of cultured human endothelial cells.

2002

Small GTP-binding Rho GTPases regulate important signaling pathways in endothelial cells, but little is known about their role in endothelial cell apoptosis. Clostridial cytotoxins specifically inactivate GTPases by glucosylation [ Clostridium difficile toxin B-10463 (TcdB-10463), C. difficile toxin B-1470 (TcdB-1470)] or ADP ribosylation ( C. botulinum C3 toxin). Exposure of human umbilical cord vein endothelial cells (HUVEC) to TcdB-10463, which inhibits RhoA/Rac1/Cdc42, or to C3 toxin, which inhibits RhoA, -B, -C, resulted in apoptosis, whereas inactivation of Rac1/Cdc42 with TcdB-1470 was without effect, suggesting that Rho inhibition was responsible for endothelial apoptosis. Disruptio…

Pulmonary and Respiratory Medicinerac1 GTP-Binding Proteinrho GTP-Binding ProteinsProgrammed cell deathUmbilical VeinsEndotheliumPhysiologyBacterial ToxinsCASP8 and FADD-Like Apoptosis Regulating ProteinApoptosisBcl-2-associated X proteinBacterial ProteinsPhysiology (medical)Proto-Oncogene ProteinsmedicineCyclic AMPIn Situ Nick-End LabelingHumanscdc42 GTP-Binding ProteinCells Culturedbcl-2-Associated X ProteinAdenosine Diphosphate RibosebiologyCaspase 3Intracellular Signaling Peptides and ProteinsCell BiologyCaspase 9Cell biologyNeoplasm ProteinsEndothelial stem cellmedicine.anatomical_structureCdc42 GTP-Binding ProteinProto-Oncogene Proteins c-bcl-2Cell cultureApoptosisCaspasesbiology.proteinMyeloid Cell Leukemia Sequence 1 ProteinEndothelium VascularSignal transductionCarrier ProteinsrhoA GTP-Binding ProteinBH3 Interacting Domain Death Agonist ProteinSignal TransductionAmerican journal of physiology. Lung cellular and molecular physiology
researchProduct